Impact of accelerated titration of guideline directed medical therapy on reverse remodeling for acute heart failure

Impact of accelerated titration of guideline directed medical therapy on reverse remodeling for acute heart failure - MANUAL study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053725

Enrollment

100

Registered

2024-03-01

Start date

2024-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HFrEF

Interventions

Usual care group prescribes ACE-I ARB or ARNi be-ta-blocker MRA and SGLT2 inhibitor in that order. The Accelerated care group prescribes SGLT2 inhibitors, MRAs, ACE-I ARBs or ARNi and beta blockers i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ADHF with LVEF less than 50% eGFR more than 30 mL/min/m2

Exclusion criteria

Exclusion criteria: Cardiogenic shockPatients taking two or more GDMT

Design outcomes

Primary

Measure	Time frame
Improvement of LVEF during 3 months	—

Countries

Japan

Contacts

Public ContactShodai Kawanami

Osaka Rosai Hospital Cardiology

mnishino@osakah.johas.go.jp072-252-3561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026